Abstract
Brain metastases represent the most common intracranial tumors in the adults. Its incidence outnumbers that of primary brain tumors by a tenfold factor. Estimated cumulative incidence is between 10 to 20% of all cancer patients, which would represent over 170 000 new cases in the US. Typically, patients with multiple brain metastases are exposed to whole brain radiation therapy, as a palliative measure. Resulting median survival improvement is modest, ranging from 3 to 5 months. This survival has not been altered despite 3 decades of clinical research aiming at improving outcome of these patients. The role of standard chemotherapy in the treatment of brain metastases has always been marginal, as the penetration of chemotherapy beyond the BBB (blood-brain barrier) is considered limited. Whereas the BBB is universally recognized as a physiological entity, its role in the treatment of brain metastases remains controversial. Metastatic lesions often depict a homogeneous intense enhancement on either CT or MRI, thus implying that the brain tumor barrier (BTB) is breached. Although there is no doubt that the BBB and BTB suffer from variable degrees of breach in integrity in the presence of malignant brain tumors, impediment to drug delivery remains, and strategy to optimize delivery must be considered if one is to really impact patient ’ s outcome in the treatment of these diseases. The intended purpose of this paper is to review current data on the role of the BBB in the treatment of CNS metastatic disease.
Keywords: Blood-brain barrier disruption, blood-brain barrier, brain metastases, chemotherapy, Convection enhanced delivery, cerebrospinal fluid, compturized tomograph, Gadolinium-DiethyleneTriamine Pentaacetic Acid, Human Epidermal growth factor Receptor 2, Magentic resonance imaging, mammalian target of rapamycin, Positron emitting tomograph, Small cell lung carcinoma, Vascular endothelial growth factor
Current Cancer Drug Targets
Title: The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Volume: 12 Issue: 3
Author(s): D. Fortin
Affiliation:
Keywords: Blood-brain barrier disruption, blood-brain barrier, brain metastases, chemotherapy, Convection enhanced delivery, cerebrospinal fluid, compturized tomograph, Gadolinium-DiethyleneTriamine Pentaacetic Acid, Human Epidermal growth factor Receptor 2, Magentic resonance imaging, mammalian target of rapamycin, Positron emitting tomograph, Small cell lung carcinoma, Vascular endothelial growth factor
Abstract: Brain metastases represent the most common intracranial tumors in the adults. Its incidence outnumbers that of primary brain tumors by a tenfold factor. Estimated cumulative incidence is between 10 to 20% of all cancer patients, which would represent over 170 000 new cases in the US. Typically, patients with multiple brain metastases are exposed to whole brain radiation therapy, as a palliative measure. Resulting median survival improvement is modest, ranging from 3 to 5 months. This survival has not been altered despite 3 decades of clinical research aiming at improving outcome of these patients. The role of standard chemotherapy in the treatment of brain metastases has always been marginal, as the penetration of chemotherapy beyond the BBB (blood-brain barrier) is considered limited. Whereas the BBB is universally recognized as a physiological entity, its role in the treatment of brain metastases remains controversial. Metastatic lesions often depict a homogeneous intense enhancement on either CT or MRI, thus implying that the brain tumor barrier (BTB) is breached. Although there is no doubt that the BBB and BTB suffer from variable degrees of breach in integrity in the presence of malignant brain tumors, impediment to drug delivery remains, and strategy to optimize delivery must be considered if one is to really impact patient ’ s outcome in the treatment of these diseases. The intended purpose of this paper is to review current data on the role of the BBB in the treatment of CNS metastatic disease.
Export Options
About this article
Cite this article as:
Fortin D., The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277511
DOI https://dx.doi.org/10.2174/156800912799277511 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies
Current Rheumatology Reviews Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology First Autochthonous case of Emerged Zoonotic Cutaneous Leishmaniasis in Mazandaran Province, Northern Iran: kDNA-PCR Evidence Base
Infectious Disorders - Drug Targets Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
Current Medicinal Chemistry Comparative Analysis of the Rabbit Endothelial Progenitor Cells from Bone Marrow and Peripheral Blood Treated with Selenium Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Renal Function, Albumin-Creatinine Ratio and Pulse Wave Velocity Predict Silent Coronary Artery Disease and Renal Outcome in Type 2 Diabetic and Prediabetic Subjects
Current Hypertension Reviews Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Antiplatelet Effects of Bioactive Compounds Present in Tomato Pomace
Current Drug Targets